Low-frequency HIV-1 drug resistance mutations in antiretroviral naïve individuals in Botswana. Issue 28 (15th July 2022)

• Record Type: Journal Article
• Authors: Maruapula, Dorcas; Seatla, Kaelo K.; Morerinyane, Olorato; Molebatsi, Kesaobaka; Giandhari, Jennifer; de Oliveira, Tulio; Musonda, Rosemary M.; Leteane, Melvin; Mpoloka, Sununguko W; Rowley, Christopher F.; Moyo, Sikhulile; Gaseitsiwe, Simani
• Is Part Of: Medicine. Volume 101:Issue 28(2022)
• Page Start: e29577
• Publication Date: 2022-07-15
• Subjects: antiretroviral naïve -- HIV drug resistance -- next-generation sequencing -- low-frequency variants; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000029577
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Background: Individuals living with human immunodeficiency virus (HIV) who experience virological failure (VF) after combination antiretroviral therapy (cART) initiation may have had low-frequency drug resistance mutations (DRMs) at cART initiation. There are no data on low-frequency DRMs among cART-naïve HIV-positive individuals in Botswana. Methods: We evaluated the prevalence of low-frequency DRMs among cART-naïve individuals previously sequenced using Sanger sequencing. The generated pol amplicons were sequenced by next-generation sequencing. Results: We observed low-frequency DRMs (detected at <20% in 33/103 (32%) of the successfully sequenced individuals, of whom four also had mutations detected at >20%. K65R was the most common low-frequency DRM detected in 8 individuals. Eighty-two of the 103 individuals had follow-up viral load data while on cART. Twenty-seven of the 82 individuals harbored low-frequency DRMs. Only 12 of 82 individuals experienced VF. The following low-frequency DRMs were observed in four individuals experiencing VF: K65R, K103N, V108I, and Y188C. No statistically significant difference was observed in the prevalence of low-frequency DRMs between individuals experiencing VF (4/12) and those not experiencing VF (23/70) ( P = .97). However, individuals with non-nucleoside reverse transcriptase inhibitors-associated low-frequency DRMs were 2.68 times more likely to experience VF (odds ratio, 2.68; 95% confidential interval, 0.4–13.9) compared with those without ( P = .22). Conclusion: Next-generation sequencing was able to detect low-frequency DRMs in this cohort in Botswana, but these DRMs did not contribute significantly to VF.